MedTrace Logo

Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity

NCT00477048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-02-22

No results posted yet for this study

Summary

Efficacy and safety of a saquinavir (SQV) based regimen in HIV-1 infected Thai patients who have chronic indinavir (IDV) associated nephrotoxicity.

Conditions

  • IDV Associated Nephrotoxicity

Interventions

DRUG

Saquinavir

SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Ministry of Health, Thailand

    collaborator OTHER_GOV

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Kiat Ruxrungtham, MD · The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477048 on ClinicalTrials.gov